DEVON, Pa., July 31, 2018 — / D.M.O. Newswire / — Zynerba Prescribed drugs, Inc. ( NASDAQ:ZYNE ), the chief in modern pharmaceutically-produced transdermal cannabinoid therapies for uncommon and near-rare neuropsychiatric problems, will host a convention name at 8:30 am EDT on Thursday August 2, 2018 to supply its second quarter enterprise and monetary replace following the just lately accomplished public providing, which closed on July 24, 2018. A press launch asserting the outcomes of the second quarter of 2018 will precede the convention name.
The decision will start at 8:30 am EDT on Thursday August 2, 2018, and can be accessible by dialing (866) 573-0180 (U.S. and Canada) or (430) 775-1345 (worldwide) and referencing convention ID 9565578. The reside webcast and replay can be made accessible on investor web page of the Firm’s web site at http://ir.zynerba.com/ . The webcast can be recorded and accessible on the Firm’s web site for 30 days.
About Zynerba Prescribed drugs, Inc.
Zynerba Prescribed drugs is the chief in pharmaceutically-produced transdermal cannabinoid therapies for uncommon and near-rare neuropsychiatric problems. We’re dedicated to enhancing the lives of sufferers and their households residing with extreme, persistent well being circumstances together with Fragile X syndrome and refractory epilepsies. Be taught extra at www.zynerba.com and observe us on Twitter at @ZynerbaPharma.